Endologix, Inc.

Endologix develops and manufactures minimally invasive treatments for aortic disorders. We have over 500 employees worldwide with Global Headquarters in Irvine, CA. Operating facilities in Santa Rosa, CA, The Netherlands and Singapore. Founded in 1992, Endologix is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. Our current product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA) and are protected by more than 108 patents. AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. AAA accounts for approximately 11,000 deaths each year in the United States, with mortality rates from ruptured AAAs reaching up to 90%. PRODUCT SAFETY INFORMATION Ovation safety information: https://endologix.com/safety-information-ovation/#use AFX safety information: https://endologix.com/safety-information-afx/#use Nellix safety information: https://endologix.com/united-states/products/nellix/